Meclozine

Antiemetic — RESPIRATORY SYSTEM

Key facts

Meclozine is an ofp drug in the Antiemetic class catalogued in DrugCentral. It was first approved by the FDA in 1957. DrugCentral lists 4 molecular targets, including Nr1i3, NR1I3 and HPN. Recorded indications include Motion sickness, Prevention of motion sickness and Vertigo.

• Approval status: ofp (first approved 1957 by the FDA).
• Drug class: Antiemetic.
• Molecular targets: Nr1i3, NR1I3, HPN and HRH1 (4 listed in DrugCentral).
• Indications: Motion sickness, Prevention of motion sickness and Vertigo.
• ATC code: R06AE05 (Piperazine derivatives).
• Molecular formula: C25H27ClN2; molecular weight 390.96 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Motion sickness
• Prevention of motion sickness
• Vertigo

Contraindications (6)

• Angle-closure glaucoma
• Benign prostatic hyperplasia
• Bladder outflow obstruction
• Chronic idiopathic constipation
• Pyloric obstruction
• Retention of urine

Mechanism & targets

• Established pharmacologic class: Antiemetic

Molecular targets (4)

Target	Gene	Action	Activity
Constitutive androstane receptor	Nr1i3	agonist	EC50 7.60
Nuclear receptor subfamily 1 group I member 3	NR1I3	antagonist	IC50 7.16
Serine protease hepsin	HPN	unknown	IC50 5.70
Histamine H1 receptor	HRH1	antagonist	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1957-02-14	FDA	—	CITRON PHARMA LLC

ATC classification

ATC code	Therapeutic hierarchy
R06AE05	RESPIRATORY SYSTEM › ANTIHISTAMINES FOR SYSTEMIC USE › ANTIHISTAMINES FOR SYSTEMIC USE › Piperazine derivatives
R06AE55	RESPIRATORY SYSTEM › ANTIHISTAMINES FOR SYSTEMIC USE › ANTIHISTAMINES FOR SYSTEMIC USE › Piperazine derivatives

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Vertigo	264.1
Dizziness	192.3
Fall	113.3
Completed suicide	91.8
Pemphigus	84.1
Hand deformity	75.6
Multiple sclerosis relapse	73.3
Synovitis	71.8
Narcotic bowel syndrome	69.5
Cerebrovascular accident	68.2
Echolalia	67.4
Off label use	63.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Meclozine is on its molecule page.

• Molecular formula: C₂₅H₂₇ClN₂
• Molecular weight: 390.96 g/mol
• CAS number: 569-65-3
• InChIKey: OCJYIGYOJCODJL-UHFFFAOYSA-N
• PubChem CID: 4034

CC1=CC=CC(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Meclozine used for?

DrugCentral lists the following indications for Meclozine: Motion sickness, Prevention of motion sickness and Vertigo.

How does Meclozine work?

Its molecular targets in DrugCentral include Nr1i3 (agonist), NR1I3 (antagonist), HPN and HRH1 (antagonist).

When was Meclozine first approved?

Meclozine was first approved by the FDA in 1957.

What drug class does Meclozine belong to?

Meclozine is in the Antiemetic class.

What is the chemical formula of Meclozine?

Meclozine has the molecular formula C25H27ClN2 and a molecular weight of 390.96 g/mol.

Sources

• DrugCentral drug card 1649 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1623 — compound record and bioactivity
• PubChem CID 4034 — chemical identifiers
• DrugBank DB00737 — drug record
• FDA UNII 3L5TQ84570 — substance identity
• DailyMed: FDA labels for Meclozine — current prescribing information (label search)
• UniProt Q14994 (NR1I3) — target protein
• UniProt P05981 (HPN) — target protein
• UniProt P35367 (HRH1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.